Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
Pp 4203 - 4216

Optimizing Surgical Outcomes: The Collaborative Role of Anesthesiologists and Pharmacists in Managing Complex Medical Conditions

[1] Saud Awwadh Althobaiti,[2] Mohammed Faleh F Alharbi,[3] Abdullah Nasser Masoud Al-Mazargah,[4] Hawra Hassan Olaiwat,[5] Rihanah Hassan Almahdi,[6] Othman Ali Hamed Almutairi,[7] Atiaf Faisal Alkhleef,[8]-Bedour Jaffar Alammari,[9]Sakinah Alawi Alawami,[10]Laila Mohammed Al-Lishlish,[11]Fahad Saeed Alshahrani,[12]Murtadha Hussain Bu Khader,[13]Muneer Moleh Alharbi,[14]Meshal Abdulaziz Alharbi,[15]Omar Sanat Alharbi

1. Pharmacy Technician Taif Health Cluster Belad Rabie Primary Health Caer Center
2. Technician Anesthesia Technology Afif General Hospital
3. Anaesthesia Technicianm Al-Farshah General Hospital
4. Anesthesia Technician Qateef Central Hospital
5. Anesthesia Technicion Qatif Central Hospital
6. Operations Technician Al Badaya General Hospital
7. Technician Anesthesia Ras Tanoura General Hospital
8. Pharmacy Technician Anak General Hospital
9. Pharmacy Technician Dammam Medical Complex
10. Pharmacy Technician Dammam Medical Complex
11. Pharmacy Technician Health Center In The City Center
12. Pharmacist King Faisal General Hospital
13. Pharmacist Al Nabhaniya General Hospital
14. Pharmacist Al-Nabhaniyah General Hospital
15. Pharmacist Al-Nabhaniyah General Hospital

Received: 10 october 2023 **Revised**: 24 November 2023 **Accepted**: 08 December 2023

Chapter 1: Introduction to Collaborative Care in Surgery

Collaborative care in surgery is a cornerstone of modern healthcare, emphasizing the combined efforts of diverse medical professionals to achieve optimal patient outcomes. Among these professionals, anesthesiologists and pharmacists play pivotal roles. Anesthesiologists oversee patient safety during surgical procedures, ensuring proper anesthesia administration and monitoring vital signs **(Bisgaard et al., 2022).** On the other hand, pharmacists bring expertise in medication management, ensuring safe and effective drug use throughout the surgical process. Their collaboration bridges critical gaps, minimizing risks and enhancing the quality of care provided to patients undergoing complex medical interventions **(Sun et al., 2020).**

In surgical settings, anesthesiologists are responsible for tailoring anesthesia plans to individual patient needs, accounting for factors such as medical history and comorbidities. This requires an intricate understanding of pharmacology, which pharmacists complement with their expertise**(Alchakee et al .,2022).** Pharmacists provide critical insights into drug interactions, dosages, and alternative medications, especially for patients with chronic illnesses or allergies. Together, they ensure that each patient receives personalized, evidence-based care that reduces the likelihood of adverse events**(Nande& Hill, 2022).**

The collaboration between anesthesiologists and pharmacists is vital for managing complex medical conditions that often accompany surgical patients. Conditions such as diabetes, cardiovascular diseases, and respiratory disorders pose additional challenges during surgery**(El Shamieh& Zgheib, 2021).** By working together, these professionals can create comprehensive plans that mitigate risks associated with these conditions. Anesthesiologists focus on maintaining hemodynamic stability, while pharmacists provide guidance on managing long-term medications during the perioperative period, ensuring continuity of care without compromising safety**(Nunez et al .,2022).**

Interdisciplinary teamwork extends beyond the operating room. During preoperative assessments, anesthesiologists rely on pharmacists to review and reconcile patients' medication lists. This process helps identify potential drug interactions or contraindications that could impact the surgery or anesthesia**(Budge, Orvets& Shields, 2020).** Pharmacists also educate patients on temporarily discontinuing specific medications and resuming them safely after the procedure. Such collaboration underscores the importance of integrating diverse expertise to ensure patient safety and readiness for surgery**(Alchakee et al .,2022).**

Effective interdisciplinary collaboration not only improves patient safety but also enhances surgical outcomes. Studies have shown that teams involving anesthesiologists and pharmacists experience fewer medication errors and postoperative complications**(Furukawa et al .,2022).** This is particularly significant in surgeries involving high-risk patients, where the margin for error is minimal. Through shared decision-making and open communication, these professionals work towards a common goal of achieving the best possible results for each patient**(Angaroni et al .,2022).**

One of the primary challenges in managing complex medical conditions during surgery is the dynamic nature of patients' needs. This requires real-time problem-solving and adaptability, areas where the collaboration between anesthesiologists and pharmacists becomes indispensable**(Barandouzi et al .,2020).** Anesthesiologists monitor patients' conditions throughout the procedure, while pharmacists are often consulted to adjust medication dosages or provide alternatives as unexpected situations arise. This synergistic approach minimizes delays and ensures uninterrupted patient care**(West et al .,2023).**

The importance of interdisciplinary collaboration is further highlighted by the increasing complexity of modern surgical procedures. Advances in medical technology and pharmacology have expanded treatment options but also introduced new challenges **(Zhang et al .,2022).** Anesthesiologists and pharmacists must stay updated on the latest developments to provide cutting-edge care. Their combined expertise allows them to navigate these complexities, ensuring that patients benefit from innovative surgical techniques and therapies without unnecessary risks **(Zhang et al.,2022).**

Effective collaboration requires a strong foundation of mutual respect and understanding between anesthesiologists and pharmacists. Each professional must appreciate the other's expertise and actively seek their input**(Leichsenring et al .,2022).**For instance, anesthesiologists often consult pharmacists for recommendations on premedication regimens or postoperative pain management strategies. Similarly, pharmacists rely on anesthesiologists' insights into a patient's physiological status to make informed decisions about medication adjustments. This reciprocal relationship fosters a culture of teamwork and continuous improvement **(Kalthoff et al .,2022).**

Training and education play a crucial role in promoting interdisciplinary collaboration. Both anesthesiologists and pharmacists undergo rigorous training, but opportunities for joint learning experiences remain limited**(Gordon & Cleland, 2021).** Incorporating interdisciplinary modules in medical and pharmacy curricula could bridge this gap. Workshops, simulations, and case studies focused on collaborative care in surgery can help build trust and improve communication skills, preparing future professionals to work effectively as a team**(Blazy, Ellingrod& Ward, 2022).**

In conclusion, the collaboration between anesthesiologists and pharmacists in surgical settings exemplifies the power of interdisciplinary teamwork in modern healthcare. By combining their unique skill sets, these professionals address the multifaceted challenges of managing complex medical

conditions during surgery**(Fabbri& Serretti, 2020a).**Their partnership not only enhances patient safety and surgical outcomes but also sets a benchmark for effective collaborative care. As the healthcare landscape continues to evolve, fostering and strengthening such collaborations will remain essential for delivering high-quality, patient-centered care**(John et al .,2022).**

Chapter 2: Preoperative Optimization: Medication Management and Risk Assessment

Preoperative optimization is a critical phase in surgical care that directly impacts patient outcomes. Effective collaboration between anesthesiologists and pharmacists during this stage ensures that patients are well-prepared for surgery, minimizing risks and enhancing recovery**(Blazy, Ellingrod& Ward, 2022).** This phase involves detailed planning, addressing patients' underlying medical conditions, and tailoring interventions to individual needs. Anesthesiologists provide expertise in evaluating physiological readiness, while pharmacists contribute to medication management and reconciliation. Together, they create a cohesive approach to reducing complications and improving surgical success rates**(Stephan et al .,2020**).

Collaboration between healthcare professionals during preoperative preparation ensures a comprehensive understanding of a patient's medical history and current health status. Anesthesiologists assess the patient's overall risk, including cardiac, respiratory, and metabolic factors, while pharmacists focus on optimizing medication regimens**(Fabbri& Serretti, 2020b).** Through effective communication and shared decision-making, potential issues such as drug interactions, allergies, or contraindications can be identified and addressed. This teamwork ultimately improves safety and reduces surgical delays**(Emond et al .,2023).**

Anesthesiologists play a pivotal role in assessing surgical risk. They evaluate factors such as cardiovascular health, respiratory function, and the potential for adverse reactions to anesthesia**(Magarbeh et al .,2023).** By conducting thorough preoperative assessments, anesthesiologists identify high-risk patients and develop individualized anesthesia plans. Their expertise ensures that patients are appropriately prepared for the physiological stress of surgery, reducing perioperative complications and enhancing overall outcomes**(Quigley et al .,2021).**

Pharmacists are essential in ensuring accurate medication reconciliation before surgery. This process involves reviewing and verifying a patient's medication list, including prescription drugs, over-the-counter medications, and herbal supplements**(Kim et al .,2022).** Pharmacists identify potential drug interactions, ensure dosages are appropriate, and adjust medications as necessary for the surgical context. Their expertise minimizes the risk of adverse drug events and enhances patient safety**(Emran et al .,2022).**

Patients with chronic conditions such as diabetes, hypertension, or cardiovascular disease require special attention during preoperative preparation. Anesthesiologists and pharmacists work together to optimize these conditions, adjusting medications and ensuring stability before surgery**(Xiao et al .,2021).** For instance, pharmacists may recommend adjustments to antihypertensive regimens, while anesthesiologists assess the impact of these changes on anesthesia and perioperative care**(Teske et al .,2022).**

One of the most critical aspects of preoperative medication management involves anticoagulants and blood thinners. Pharmacists and anesthesiologists collaborate to balance the risks of bleeding with the need for thromboembolism prevention**(Jansen et al .,2019).** Pharmacists provide guidance on the timing of medication discontinuation and reinitiation, while anesthesiologists ensure appropriate strategies are in place to manage potential bleeding complications during surgery**(King et al .,2023).**

Patient education is a vital component of preoperative optimization. Pharmacists and anesthesiologists jointly educate patients about the importance of medication adherence and necessary adjustments before surgery. This includes informing patients about fasting requirements, medication schedules, and the rationale behind any changes. Clear communication empowers patients to actively participate in their care, reducing anxiety and enhancing compliance**(Weir et al .,2020).**

Preoperative clinics provide a structured environment for anesthesiologists and pharmacists to collaborate effectively. These clinics allow for thorough patient evaluations, comprehensive medication reviews, and the development of individualized care plans. By leveraging the expertise of both professionals, preoperative clinics streamline the optimization process, ensuring all patients are adequately prepared for surgery**(Soler et al .,2022).**

Advancements in technology, such as electronic health records (EHRs) and clinical decision support systems, enhance the collaborative efforts of anesthesiologists and pharmacists**(Elkassabany et al .,2019).** These tools facilitate seamless communication, improve access to patient data, and provide alerts for potential drug interactions or risks. By integrating technology into preoperative care, healthcare teams can further enhance efficiency and patient safety**(Stennett, Back& Race, 2022).**

Future advancements in preoperative optimization will likely focus on personalized medicine and predictive analytics. Anesthesiologists and pharmacists can utilize genetic testing and advanced algorithms to tailor interventions to individual patient profiles**(Guttman, Nudel& Kerem, 2019).** Additionally, ongoing research and training initiatives will further strengthen their collaboration, ensuring continuous improvement in surgical outcomes. As healthcare evolves, the partnership between anesthesiologists and pharmacists will remain integral to delivering safe, high-quality care**(Scarborough et al .,2023).**

Chapter 3: Intraoperative Collaboration: Enhancing Patient Safety and Surgical Outcomes

Intraoperative collaboration between anesthesiologists and pharmacists is critical to ensuring patient safety during surgical procedures. Effective real-time communication facilitates rapid decision-making, particularly in managing complex cases that require dynamic adjustments to medication regimens **(D'Ambrosio et al .,2022).**By working closely together, anesthesiologists provide updates on the patient's physiological responses, while pharmacists recommend the most appropriate medications and dosages to achieve optimal outcomes. This synergistic relationship reduces errors, enhances efficiency, and ensures patient-centered care during surgery**(Rajer& Sandegren, 2022).**

Effective communication between anesthesiologists and pharmacists during surgery is a cornerstone of patient safety. This real-time dialogue is essential in scenarios where sudden changes in a patient's condition require immediate intervention **(Ramos, Sadeghi& Tabatabaeian, 2021).** Pharmacists, equipped with comprehensive knowledge of pharmacokinetics and pharmacodynamics, provide critical insights that complement the anesthesiologist's expertise. This collaboration ensures the accurate selection and administration of medications, minimizing risks associated with drug interactions and adverse effects**(Leichsenring et al .,2022).**

One of the primary benefits of intraoperative collaboration is the management of complex medication challenges. Surgical patients often present with comorbidities requiring multiple medications, increasing the potential for drug interactions**(Griffith& Feyman, 2021).** Pharmacists play a vital role in identifying and mitigating these risks by providing tailored recommendations based on the patient's medical history. Their input helps anesthesiologists adjust anesthesia plans to avoid complications and enhance overall surgical outcomes**(Vanacker, Lenuzza& Rasigade, 2023).**

Intraoperative medication challenges frequently arise due to the unpredictable nature of surgical procedures. For example, sudden changes in blood pressure or heart rate may necessitate immediate pharmacological intervention**(Heckman, Davis& Crowson, 2022).** The collaboration between anesthesiologists and pharmacists ensures that these interventions are not only timely but also precise. Pharmacists can quickly prepare and verify medications while anesthesiologists focus on monitoring the patient's vital signs, creating a seamless workflow in the operating room**(Strobl et al .,2022).**

Complications during surgery, such as allergic reactions or unexpected bleeding, often demand rapid responses to prevent adverse outcomes. In such cases, anesthesiologists rely on pharmacists to provide evidence-based recommendations for alternative medications or dosages. This real-time collaboration is

particularly valuable when dealing with rare or unfamiliar drugs, ensuring that every decision aligns with best practices and patient safety standards**(Blake et al .,2020).**

The integration of advanced technologies, such as computerized physician order entry (CPOE) systems and clinical decision support tools, further enhances intraoperative collaboration **(Canbek et al .,2019).** These systems allow pharmacists and anesthesiologists to access real-time patient data, improving their ability to make informed decisions. Pharmacists can use these tools to detect potential medication errors before they occur, providing an additional layer of safety in the operating room**(Ricardo-Silgado et al .,2022).**

Pain management during surgery is another area where collaboration between anesthesiologists and pharmacists proves invaluable. Anesthesiologists focus on administering anesthetics, while pharmacists ensure the availability of adjunct medications to control pain and minimize side effects**(Zhang et al .,2019).** This partnership not only enhances the patient's comfort during surgery but also reduces the risk of postoperative complications such as chronic pain or opioid dependence**(Almomani et al .,2022).**

The management of blood products and fluids is a critical aspect of intraoperative care. Pharmacists contribute by ensuring the proper selection and dosing of anticoagulants, clotting agents, and volume expanders**(Bojaxhi 2019).** Anesthesiologists, in turn, provide continuous feedback on the patient's response, enabling precise adjustments to treatment plans. This teamwork is essential in maintaining hemodynamic stability and preventing complications such as excessive bleeding or clot formation**(Botton et al .,2021).**

Education and training play a significant role in fostering effective intraoperative collaboration. Regular interdisciplinary workshops and simulations allow anesthesiologists and pharmacists to practice communication skills and refine their workflows. These activities build mutual trust and understanding, ensuring that both parties can work seamlessly together during high-pressure surgical situations**(Liu et al .,2022).**

The importance of documentation and accountability cannot be overlooked in intraoperative care. Pharmacists assist anesthesiologists by maintaining accurate records of medications used during surgery, including dosages and times of administration. This meticulous documentation is crucial for evaluating surgical outcomes and identifying areas for improvement, ultimately enhancing the quality of care delivered to patients**(Maltas et al .,2023).**

Cultural and organizational factors also influence the effectiveness of intraoperative collaboration. Hospitals that prioritize interdisciplinary teamwork and allocate resources to support pharmacist-anesthesiologist partnerships tend to achieve better surgical outcomes**(Ju et al .,2019).** By fostering a culture of open communication and mutual respect, healthcare institutions can create an environment where collaboration thrives, benefiting both patients and providers**(Johnson et al .,2022).**

In conclusion, real-time collaboration between anesthesiologists and pharmacists during surgery is essential for managing medication challenges and complications. This partnership enhances patient safety, improves surgical outcomes, and streamlines intraoperative workflows**(Bousman, Maruf& Müller, 2019).** As healthcare continues to evolve, investing in tools, training, and organizational strategies to support this collaboration will be vital in ensuring the highest standards of surgical care**(Angermayr et al .,2022).**

Chapter 4: Postoperative Care: Managing Complications and Enhancing Recovery

Postoperative care is a critical phase of the surgical process that determines patient recovery and long-term outcomes. It focuses on managing complications such as pain, infection, and impaired mobility. Anesthesiologists and pharmacists play essential roles in ensuring optimal patient care during this phase **(Gloor et al .,2022).** The complexity of postoperative management requires coordinated efforts between healthcare professionals to address both anticipated and unexpected challenges. Effective communication among the surgical team, nurses, and pharmacists ensures timely identification and management of complications, promoting faster recovery and reducing hospital stays**(Labrie et al .,2022).**

Pain management is one of the foremost challenges in postoperative care. Poorly controlled pain can lead to delayed recovery and increased patient distress. Anesthesiologists design pain control strategies tailored to individual needs, including multimodal analgesia, patient-controlled analgesia, and regional anesthesia**(Maltas et al .,2023).** Pharmacists support this process by ensuring the safe and effective use of pain medications, monitoring for potential drug interactions, and providing guidance on appropriate dosing. The collaboration between these professionals minimizes the risk of opioid misuse and improves patient comfort**(Gutiérrez-Rojas et al .,2020).**

Infections are a major concern following surgery, often leading to extended hospital stays and higher healthcare costs. Pharmacists and anesthesiologists work together to prevent and manage infections through proactive measures. Pharmacists ensure the timely administration of prophylactic antibiotics while monitoring for resistance or adverse reactions**(Wang, Chen& Ma, 2019).** Anesthesiologists contribute by maintaining sterile techniques and addressing any intraoperative factors that increase infection risks. This teamwork enhances patient safety and reduces the burden of postoperative infections(**Häusler et al .,2022).**

Another critical aspect of postoperative care is preventing venous thromboembolism (VTE), a potentially fatal complication. Pharmacists play a key role in managing anticoagulation therapy, ensuring appropriate dosing, and educating patients about the importance of adherence**(Jukic et al .,2019).** Anesthesiologists monitor for signs of clotting during surgery and recommend preventive measures such as compression devices and early mobilization. This collaborative approach significantly reduces the incidence of VTE and its associated complications**(Islam et al .,2022).**

Proper nutrition is essential for recovery, as it helps in wound healing and restores energy levels. Pharmacists contribute by advising on nutritional supplements and managing drug-nutrient interactions. Anesthesiologists ensure that patients are medically stable to resume oral intake post-surgery. By working together, these professionals help establish nutritional protocols that promote faster recovery and prevent complications related to malnutrition**(Li et al .,2020).**

Discharge planning is a crucial part of postoperative care, where pharmacists take a leading role. They educate patients about their medications, emphasizing adherence, potential side effects, and interactions**(Brown et al .,2019).** Pharmacists also ensure that prescriptions are accurate and tailored to the patient's needs, minimizing risks during the transition from hospital to home. By empowering patients with knowledge, pharmacists contribute to better long-term outcomes and reduced readmission rates**(Järvinen et al .,2022).**

Postoperative pain often persists after discharge, requiring continued management. Pharmacists assist patients in understanding the proper use of prescribed painkillers and non-pharmacological interventions such as physical therapy. They monitor for signs of opioid dependency or misuse, providing recommendations for tapering off medications when necessary. This proactive approach ensures sustained pain relief without compromising patient safety**(Falyar, 2023).**

Encouraging early mobilization is vital for preventing complications such as muscle atrophy and pulmonary embolism. Anesthesiologists assess pain levels and provide regional anesthesia to facilitate movement, while pharmacists manage medications that may impact physical activity, such as muscle relaxants or sedatives. By aligning their efforts, they help patients regain mobility more quickly and safely**(Yu et al .,2020).**

Effective patient education is at the heart of successful postoperative care. Pharmacists provide detailed instructions on medication regimens, while anesthesiologists clarify the importance of follow-up appointments and recognizing warning signs of complications. This joint effort empowers patients to take an active role in their recovery, improving adherence to prescribed treatments and reducing the likelihood of complications**(Lam et al .,2020).**

Postoperative recovery is not solely physical; psychological challenges such as anxiety and depression can hinder progress. Pharmacists may recommend suitable medications or supplements, while

anesthesiologists address stress-related symptoms using non-pharmacological approaches such as mindfulness techniques. Collaborative care in this area enhances both mental and physical recovery, leading to better overall outcomes**(Farrokhian et al .,2022).**

Advancements in technology, such as electronic health records and telemedicine, have transformed postoperative care. Pharmacists and anesthesiologists utilize these tools to monitor patient progress, adjust medication plans, and ensure timely interventions. Telemedicine enables virtual consultations, allowing professionals to address patient concerns without the need for frequent hospital visits. These innovations enhance care quality and patient satisfaction**(Ma et al .,2020).**

The future of postoperative care lies in strengthening the collaboration between anesthesiologists and pharmacists. Continued research and the adoption of evidence-based practices will further refine strategies for managing complications and enhancing recovery**(Jarvis, Peter& Shaman, 2019).** Emerging technologies, such as artificial intelligence and personalized medicine, hold the potential to revolutionize postoperative care. By embracing these advancements, healthcare professionals can continue to improve outcomes and elevate the standard of care**(Min et al .,2021).**

Chapter 5: Future Directions: Innovations in Collaborative Practices and Research

The integration of emerging technologies in healthcare is transforming the way anesthesiologists and pharmacists collaborate to optimize surgical outcomes. Digital health tools, such as electronic health records (EHRs), enable seamless communication between these professionals, ensuring accurate medication management and patient safety during surgeries**(Daripally& Peddi, 2020).**Artificial intelligence (AI)-driven algorithms are also playing a pivotal role by analyzing patient data to predict complications and optimize drug regimens. These technologies streamline workflows, reduce errors, and enhance decision-making, setting a new standard for interdisciplinary collaboration**(Greden et al .,2019).**

Telemedicine has emerged as another promising tool to strengthen anesthesiologist-pharmacist collaboration. Preoperative consultations conducted via telemedicine allow pharmacists and anesthesiologists to work together remotely, reviewing patient histories and medication plans**(Das et al .,2020).** This approach is particularly valuable in rural and underserved areas, where access to specialists may be limited. Telemedicine not only improves communication but also ensures timely intervention, ultimately leading to better surgical outcomes and enhanced patient care**(Kim et al .,2022).**

The adoption of pharmacogenomics is revolutionizing personalized medicine and could significantly enhance anesthesiologist-pharmacist collaboration. By analyzing a patient's genetic profile, pharmacists can recommend tailored drug regimens, while anesthesiologists adjust anesthesia plans accordingly**(Allen et al .,2019).** This collaborative approach minimizes adverse drug reactions and ensures optimal dosing, particularly in patients with complex medical conditions. Continued research in pharmacogenomics will likely lead to more precise and effective perioperative care strategies**(Hussain et al .,2023).**

Simulation-based training programs represent a future avenue for improving interdisciplinary collaboration between anesthesiologists and pharmacists. By participating in simulated surgical scenarios, teams can practice real-time communication, decision-making, and crisis management**(Thota et al .,2019).** These simulations not only improve individual skills but also foster trust and understanding between team members, leading to better outcomes during actual surgeries. Expanding access to such training programs could standardize best practices in collaborative care**(Boin et al .,2021).**

The use of clinical decision support systems (CDSS) offers another opportunity to enhance collaboration. These AI-driven platforms provide real-time recommendations on drug interactions, dosages, and potential complications during surgery. Pharmacists can input medication data into the system, while anesthesiologists use the insights to adjust anesthesia plans. CDSS ensures that both professionals work from the same data set, reducing errors and improving patient safety**(Hicks et al .,2020).**

One area requiring further research is the development of standardized protocols for anesthesiologist-pharmacist collaboration. Currently, practices vary widely across institutions, leading to inconsistencies in patient care. By identifying best practices and codifying them into standardized guidelines, healthcare systems can ensure that collaboration is effective and universally applied. This research could serve as a foundation for national and international policies on interdisciplinary surgical care**(Gill et al .,2020).**

Another important research avenue is exploring the impact of collaboration on patient outcomes in diverse populations. Understanding how factors like age, comorbidities, and socioeconomic status influence surgical outcomes could help anesthesiologists and pharmacists tailor their approaches. This data-driven research would provide insights into addressing health disparities and ensuring equitable care for all surgical patients**(Bisgaard et al .,2022).**

The role of wearable health technologies and remote monitoring devices in surgical care also deserves attention. These tools can provide real-time data on a patient's vitals and recovery progress, enabling anesthesiologists and pharmacists to adjust care plans dynamically**(Border et al .,2019).** For example, monitoring postoperative pain levels through wearable devices could guide pharmacists in optimizing pain management, while anesthesiologists ensure safe recovery from anesthesia**(Poudel et al .,2023).**

Expanding research into artificial intelligence and machine learning applications could further transform collaborative practices. AI models trained on large datasets can predict potential complications and recommend tailored interventions **(Andreescu et al .,2019).** Anesthesiologists and pharmacists could use these insights to develop proactive strategies, ensuring smoother surgical procedures and faster recoveries. Investing in such research will be critical to unlocking the full potential of AI-driven collaboration**(Bousman et al .,2021).**

As healthcare systems evolve, it is essential to focus on fostering a culture of collaboration through education and training. Interdisciplinary workshops and conferences can encourage knowledge exchange and skill development between anesthesiologists and pharmacists **(Aldrich et al .,2019).** Additionally, introducing courses on teamwork and communication in medical and pharmacy schools can prepare future professionals for collaborative practices. By prioritizing education and research, the healthcare industry can create a future where anesthesiologist-pharmacist collaboration is not just an ideal but a standard practice**(El-Kefraoui et al .,2020).**

References

1. **Alchakee, A., Ahmed, M., Eldohaji, L., Alhaj, H., & Saber-Ayad, M. (2022).** Pharmacogenomics in Psychiatry Practice: The Value and the Challenges. International Journal of Molecular Sciences, 23(21), 13485.
2. **Aldrich, S. L., Poweleit, E. A., Prows, C. A., Martin, L. J., Strawn, J. R., & Ramsey, L. B. (2019).** Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. Frontiers in Pharmacology, 10.
3. **Allen, K., Baban, A., Munjiza, J., & Pappa, S. (2019).** Management of AntipsychoticRelated Sexual Dysfunction: Systematic Review. The Journal of Sexual Medicine, 16(12), 1978–1987.
4. **Andreescu, C., Ajilore, O., Aizenstein, H. J., Albert, K., Butters, M. A., Landman, B. A., Karim, H. T., Krafty, R., & Taylor, W. D. (2019).** Disruption of Neural Homeostasis as a Model of Relapse and Recurrence in Late-Life Depression. The American Journal of Geriatric Psychiatry, 27(12), 1316–1330.
5. **Barandouzi, Z. A., Starkweather, A. R., Henderson, W. A., Gyamfi, A., & Cong, X. S. (2020).** Altered Composition of Gut Microbiota in Depression: A Systematic Review. Frontiers in Psychiatry, 11, 541.
6. **Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022).** Depression and anxiety in inflammatory bowel disease: Epidemiology, mechanisms and treatment. Nature Reviews Gastroenterology & Hepatology, 19(11), Article 11.
7. **Blake, L. E., Roux, J., Hernando-Herraez, I., Banovich, N. E., Perez, R. G., Hsiao, C. J., Eres, I., Cuevas, C., Marques-Bonet, T., & Gilad, Y. (2020).** A comparison of gene expression and DNA methylation patterns across tissues and species. Genome Research, 30(2), 250–262.

8. **Blazy, C., Ellingrod, V., & Ward, K. (2022).** Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics. Frontiers in Pharmacology, 13.
9. **Border, R., Johnson, E. C., Evans, L. M., Smolen, A., Berley, N., Sullivan, P. F., & Keller, M. C. (2019).** No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples. The American Journal of Psychiatry, 176(5), 376–387.
10. **Botton, M. R., Whirl-Carrillo, M., Del Tredici, A. L., Sangkuhl, K., Cavallari, L. H., Agúndez, J. A. G., Duconge, J., Lee, M. T. M., Woodahl, E. L., ClaudioCampos, K., Daly, A. K., Klein, T. E., Pratt, V. M., Scott, S. A., & Gaedigk, A. (2021).** PharmVar GeneFocus: CYP2C19. Clinical Pharmacology and Therapeutics, 109(2), 352–366.
11. **Bousman, C. A., Bengesser, S. A., Aitchison, K. J., Amare, A. T., Aschauer, H., Baune, B. T., Asl, B. B., Bishop, J. R., Burmeister, M., Chaumette, B., Chen, L.-S., Cordner, Z. A., Deckert, J., Degenhardt, F., DeLisi, L. E., Folkersen, L., Kennedy, J. L., Klein, T. E., McClay, J. L., … Müller, D. J. (2021).** Review andConsensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 54(1), 5–17.
12. **Bousman, C., Maruf, A. A., & Müller, D. J. (2019).** Towards the integration of pharmacogenetics in psychiatry: A minimum, evidence-based genetic testing panel. Current Opinion in Psychiatry, 32(1), 7–15.
13. **Brown, L., Eum, S., Haga, S. B., Strawn, J. R., & Zierhut, H. (2019).** Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry. Pharmacopsychiatry.
14. **El Shamieh, S., & Zgheib, N. K. (2021).** Pharmacogenetics in developing countries and low resource environments. Human Genetics.
15. **Fabbri, C., & Serretti, A. (2020a).** Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. Neuroscience Letters, 726, 133651.
16. **Fabbri, C., & Serretti, A. (2020b).** Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. Clinical Psychopharmacology and Neuroscience, 18(1), 1–9.
17. **Furukawa, Y., Oguro, S., Obata, S., Hamza, T., Ostinelli, E. G., & Kasai, K. (2022).** Optimal dose of brexpiprazole for augmentation therapy of antidepressantrefractory depression: A systematic review and dose-effect meta-analysis. Psychiatry and Clinical Neurosciences, 76(9), 416–422.
18. **Gill, H., Gill, B., El-Halabi, S., Chen-Li, D., Lipsitz, O., Rosenblat, J. D., Van Rheenen, T. E., Rodrigues, N. B., Mansur, R. B., Majeed, A., Lui, L. M. W., Nasri, F., Lee, Y., & Mcintyre, R. S. (2020).** Antidepressant Medications and Weight Change: A Narrative Review. Obesity, 28(11), 2064–2072.
19. **Gloor, Y., Lloret-Linares, C., Bosilkovska, M., Perroud, N., Richard-Lepouriel, H., Aubry, J.-M., Daali, Y., Desmeules, J. A., & Besson, M. (2022).** Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants. Biomedicine & Pharmacotherapy, 152, 113202.
20. **Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, K., Gilbert, A., Burns, L., Jablonski, M. R., & Dechairo, B. (2019).** Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research, 111, 59–67.
21. **Griffith, K. N., & Feyman, Y. (2021).** Amplifying the Noise: The Dangers of Post Hoc Power Analyses. The Journal of Surgical Research, 259, A9–A11.
22. **Gutiérrez-Rojas, L., Porras-Segovia, A., Dunne, H., Andrade-González, N., & Cervilla, J. A. (2020).** Prevalence and correlates of major depressive disorder: A systematic review. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil: 1999), 42(6), 657–672.
23. **Guttman, Y., Nudel, A., & Kerem, Z. (2019).** Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related. Frontiers in Genetics, 10.

24. **Heckman, M. G., Davis, J. M., & Crowson, C. S. (2022).** Post Hoc Power Calculations: An Inappropriate Method for Interpreting the Findings of a Research Study. The Journal of Rheumatology, 49(8), 867–870.
25. **Hicks, J. K., Bishop, J. R., Gammal, R. S., Sangkuhl, K., Bousman, C., Leeder, J. S., Llerena, A., Mueller, D. J., Ramsey, L. B., Scott, S. A., Skaar, T. C., Caudle, K. E., Klein, T. E., & Gaedigk, A. (2020).** A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 107(1), 50.
26. **Islam, F., Marshe, V. S., Magarbeh, L., Frey, B. N., Milev, R. V., Soares, C. N., Parikh, S. V., Placenza, F., Strother, S. C., Hassel, S., Taylor, V. H., Leri, F., Blier, P., Uher, R., Farzan, F., Lam, R. W., Turecki, G., Foster, J. A., Rotzinger, S., … Müller, D. J. (2022).** Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: Results from the CAN-BIND 1 study. Translational Psychiatry, 12(1), Article 1.
27. **Jansen, R. J., Tong, L., Argos, M., Jasmine, F., Rakibuz-Zaman, M., Sarwar, G., Islam, Md. T., Shahriar, H., Islam, T., Rahman, M., Yunus, Md., Kibriya, M. G., Baron, J. A., Ahsan, H., & Pierce, B. L. (2019).** The effect of age on DNA methylation in whole blood among Bangladeshi men and women. BMC Genomics, 20, 704.
28. **Jarvis, J. P., Peter, A. P., & Shaman, J. A. (2019).** Consequences of CYP2D6 CopyNumber Variation for Pharmacogenomics in Psychiatry. Frontiers in Psychiatry, 10.
29. **Ju, C., Fiori, L. M., Belzeaux, R., Theroux, J.-F., Chen, G. G., Aouabed, Z., Blier, P., Farzan, F., Frey, B. N., Giacobbe, P., Lam, R. W., Leri, F., MacQueen, G. M., Milev, R., Müller, D. J., Parikh, S. V., Rotzinger, S., Soares, C. N., Uher, R., … Turecki, G. (2019).** Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 9(1), Article 1.
30. **Jukic, M. M., Smith, R. L., Haslemo, T., Molden, E., & Ingelman-Sundberg, M. (2019).** Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: A retrospective, cohort study. The Lancet Psychiatry, 6(5), 418– 426.
31. **Kim, H. K., Zai, G., Müller, D. J., Husain, M. I., Lam, R. W., Frey, B. N., Soares, C. N., Parikh, S. V., Milev, R., Foster, J. A., Turecki, G., Farzan, F., Mulsant, B. H., Kennedy, S. H., Tripathy, S. J., & Kloiber, S. (2022).** Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study. Pharmacopsychiatry, 55(6), 297– 303.
32. **Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022).** The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry, 21(1), 133–145.
33. **Boin, M. A., Mehta, D., Dankert, J., Umeh, U. O., Zuckerman, J. D., & Virk, M. S. (2021).** Anesthesia in total shoulder arthroplasty: A systematic review and meta-analysis. JBJS Reviews, 9(11), 10.2106/JBJS.RVW.21.00115.
34. **Bojaxhi, E., Lumermann, L. A., Mazer, L. S., Howe, B. L., Ortiguera, C. J., & Clendenen, S. R. (2019).** Interscalene brachial plexus catheter versus single-shot interscalene block with periarticular local infiltration analgesia for shoulder arthroplasty. Minerva Anestesiologica, 85(8), 840–845.
35. **Budge, M., Orvets, N., & Shields, E. (2020).** Single-shot liposomal bupivacaine interscalene nerve block provides equivalent pain relief compared to continuous catheter interscalene nerve block in total shoulder arthroplasty. Seminars in Arthroplasty: JSES, 30 (4), 285- 290.
36. **Canbek, U., Akgun, U., Aydogan, N. H., Kilinc, C. Y., & Uysal, A. I. (2019).** Continuous adductor canal block following total knee arthroplasty provides better analgesia compared to single shot: A prospective randomized controlled trial. Acta Orthopaedica et Traumatologica Turcica, 53(5), 334–339.
37. **Elkassabany, N. M., Cai, L. F., Badiola, I., Kase, B., Liu, J., Hughes, C., Israelite, C. L., & Nelson, C. L. (2019).** A prospective randomized open-label study of single injection versus continuous adductor canal block for postoperative analgesia after total knee arthroplasty. The Bone & Joint Journal, 101-B(3), 340–347.

38. **El-Kefraoui, C., Olleik, G., Chay, M. A., Kouyoumdjian, A., Nguyen-Powanda, P., Rajabiyazdi, F., Do, U., Derksen, A., Landry, T., Amar-Zifkin, A., Ramanakumar, A. V., Martel, M. O., Baldini, G., Feldman, L., & Fiore, J. F., Jr (2020).** Opioid versus opioid-free analgesia after surgical discharge: Protocol for a systematic review and meta-analysis. BMJ Open, 10(1), e035443.
39. **Falyar, C. R. (2023).** Regional anesthesia: Upper extremity, lower extremity, and truncal blocks. In S. Elisha, J. Heiner, & J. Nagelhout (Eds.), Nurse anesthesia (7th ed., pp. 1141–1175). Elsevier
40. **Gordon, L., & Cleland, J. A. (2021).** Change is never easy: How management theories can help operationalize change in medical education. Medical Education, 55(1), 55–64.
41. **Häusler, G., van der Vet, P. C. R., Beeres, F. J. P., Kaufman, T., Kusen, J. Q., & Poblete, B. (2022).** The impact of loco-regional anaesthesia on postoperative opioid use in elderly hip fracture patients: An observational study. European Journal of Trauma and Emergency Surgery: Official Publication of the European Trauma Society, 48(4), 2943– 2952.
42. **Hussain, N., Brull, R., Zhou, S., Schroell, R., McCartney, C., Sawyer, T., & Abdallah, F. W. (2023).** Analgesic benefits of single-shot versus continuous adductor canal block for total knee arthroplasty: A systemic review and meta-analysis of randomized trials. Regional Anesthesia and Pain Medicine, 48(2), 49–60.
43. **Kalthoff, A., Sanda, M., Tate, P., Evanson, K., Pederson, J. M., Paranjape, G. S., Patel, P. D., Sheffels, E., Miller, R., & Gupta, A. (2022).** Peripheral nerve blocks outperform general anesthesia for pain control in arthroscopic rotator cuff repair: A systematic review and meta-analysis. Arthroscopy: The Journal of Arthroscopic & Related Surgery: Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 38(5), 1627–1641.
44. **Lam, H. Y. J., Tang, Y. H. B., Wong, H. L., & Yang, I. B. (2020).** Similar early functional recovery after total knee replacement comparing single shot versus continuous saphenous nerve block: A randomized, double-blind trial. Journal of Orthopaedic Surgery (Hong Kong), 28(2), 2309499020932037.
45. **Li, S., Zhou, J., Li, X., Teng, X., Li, Y., Du, C., & Zhu, J. (2020).** Analgesic impact of singleshot versus continuous femoral nerve block after total knee arthroplasty: A systematic review and meta-analysis. Advances in Therapy, 37(2), 671–685.
46. **Ma, T., Liu, Q., Zhou, L., Yue, K., Ding, Z., & Chen, B. (2020).** Continuous nerve block versus single-shot nerve block for total knee arthroplasty: A meta-analysis from randomized controlled trials. Minerva Anestesiologica, 86(2), 205–216.
47. **Quigley, D. D., Elliott, M. N., Slaughter, M. E., Burkhart, Q., Chen, A. Y., Talamantes, E., & Hays, R. D. (2021).** Shadow coaching improves patient experience with care, but gains erode later. Medical Care, 59(11), 950–960.
48. **Soler, J., Sciortino, N., Badaglialacqua, S., Ryan, C., & Marchand, G. (2022).** Analgesic efficacy of multiple single-shot peripheral nerve blocks on postoperative short-term opioid usage and clinical outcomes in a suburban hospital setting. Journal of Clinical Medicine Research, 14(6), 219–228.
49. **Stephan, S. R., Garlich, J. M., Debbi, E. M., Johnson, C. R., Polakof, L. S., Noorzad, A. S., Moak, Z. B., Yalamanchili, D. R., Stephenson, S. K., Anand, K. K., Lin, C. A., Little, M. T. M., & Moon, C. N. (2020).** A Comparison in outcomes of preoperative single-shot versus continuous catheter fascia iliaca regional anesthesia in geriatric hip fracture patients. Injury, 51(6), 1337–1342.
50. **Sun, C., Zhang, X., Song, F., Zhao, Z., Du, R., Wu, S., Ma, Q., & Cai, X. (2020).** Is continuous catheter adductor canal block better than single-shot canal adductor canal block in primary total knee arthroplasty?: A GRADE analysis of the evidence through a systematic review and meta-analysis. Medicine, 99(20), e20320.
51. **Teske, L. G., Pill, S. G., Lutz, A., Thigpen, C. A., Shanley, E., Adams, K. J., Bohon, H., Graham, G. D., Marston, G., Walker, K. B., & Kissenberth, M. J. (2022).** Single-shot interscalene regional anesthesia provides non-inferior analgesia and decreased complications compared with an indwelling catheter for arthroscopic and reconstructive shoulder surgery. Journal of Shoulder and Elbow Surgery, 31(6S), S152–S157.

52. **Thota, R. S., Ramkiran, S., Garg, R., Goswami, J., Baxi, V., & Thomas, M. (2019).** Opioid-free onco-anesthesia: Is it time to convict opioids? A systematic review of the literature. Journal of Anaesthesiology, Clinical Pharmacology, 35(4), 441–452.
53. **Wang, C., Chen, Z., & Ma, X. (2019).** Continuous adductor canal block is a better choice compared to single shot after primary total knee arthroplasty: A meta-analysis of randomized controlled trials. International Journal of Surgery (London, England), 72, 16–24.
54. **Weir, T. B., Simpson, N., Aneizi, A., Foster, M. J., Jauregui, J. J., Gilotra, M. N., Henn Iii, R. F., & Hasan, S. A. (2020).** Single-shot liposomal bupivacaine interscalene block versus continuous interscalene catheter in total shoulder arthroplasty: Opioid administration, pain scores, and complications. Journal of Orthopaedics, 22, 261–267.
55. **Xiao, M., Cohen, S. A., Cheung, E. V., Freehill, M. T., & Abrams, G. D. (2021).** Pain management in shoulder arthroplasty: a systematic review and network meta-analysis of randomized controlled trials. Journal of Shoulder and Elbow Surgery, 30(11), 2638– 2647.
56. **Yu, R., Wang, H., Zhuo, Y., Liu, D., Wu, C., & Zhang, Y. (2020).** Continuous adductor canal block provides better performance after total knee arthroplasty compared with the singleshot adductor canal block: An updated meta-analysis of randomized controlled trials. Medicine, 99(43), e22762.
57. **Zhang, L. K., Zhang, B. Y., Quan, R. F., Xu, H., Sun, Y. J., & Zhou, J. H. (2019).** Single shot versus continuous technique adductor canal block for analgesia following total knee arthroplasty: A PRISMA-compliant meta-analysis. Medicine, 98(20), e15539.
58. **Alchakee, A., Ahmed, M., Eldohaji, L., Alhaj, H., & Saber-Ayad, M. (2022):**Pharmacogenomics in Psychiatry Practice: The Value and the Challenges.International Journal of Molecular Sciences, 23(21), 13485.
59. **Almomani, B. A., Hijazi, B. M., Awwad, O. & Khasawneh, R. A. (2022):** Prevalence and predictors of non-adherence to short-term antibiotics: A population-based survey. en. PLOS ONE 17 (ed Brusa, P.) e0268285. ISSN: 1932-6203 (May 2022).
60. **Angaroni, F. et al. (2022):** J-SPACE: a Julia package for the simulation of spatial models of cancer evolution and of sequencing experiments. en. BMC Bioinformatics 23, 269. ISSN: 1471-2105 (Dec. 2022).
61. **Angermayr, S. A. et al. (2022):** Growth-mediated negative feedback shapes quantitative antibiotic response. en. Molecular Systems Biology 18, e10490. ISSN: 1744-4292, 1744-4292 (Sept. 2022).
62. **Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022):** Depression and anxiety in inflammatory bowel disease: Epidemiology, mechanisms and treatment. Nature Reviews Gastroenterology & Hepatology, 19(11), Article 11.
63. **Blazy, C., Ellingrod, V., & Ward, K. (2022):** Variability Between Clinical Pharmacogenetics Implementation Consortium (CPICR) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics. Frontiers in Pharmacology.
64. **D'Ambrosio, F. et al. (2022):** Adherence to Antibiotic Prescription of Dental Patients: The Other Side of the Antimicrobial Resistance. en. Healthcare 10, 1636. ISSN: 22279032 (Aug. 2022).
65. **Daripally, S., & Peddi, K. (2020):** Polymorphic variants of drug-metabolizing enzymes alter the risk and survival of oral cancer patients. 3 Biotech, 10(12), 529.
66. **Das, S. G., Direito, S. O., Waclaw, B., Allen, R. J. & Krug, J. (2020):** Predictable properties of ftness landscapes induced by adaptational tradeoffs. en. eLife 9, e55155. ISSN: 2050-084X (May 2020).
67. **Emond, R. et al. (2023):** Cell facilitation promotes growth and survival under drug pressure in breast cancer. en. Nature Communications 14, 3851. ISSN: 2041-1723 (June 2023).
68. **Emran, T. B. et al. (2022):** Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Frontiers in Oncology 12, 891652. ISSN: 2234-943X (June 2022).
69. **Farrokhian, N. et al. (2022):** Measuring competitive exclusion in non–small cell lung cancer. Science Advances 8, eabm7212 (July 2022).

70. **Järvinen, E., Deng, F., Kiander, W., Sinokki, A., Kidron, H., & Sjöstedt, N. (2022):** The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates. Frontiers in Pharmacology, 12.
71. **John, T. M., Deshpande, A., Brizendine, K., Yu, P.-C. & Rothberg, M. B. (2022):** Epidemiology and Outcomes of Community-Acquired Escherichia coli Pneumonia. en. Open Forum Infectious Diseases 9, ofab597. ISSN: 2328-8957 (Jan. 2022).
72. **Johnson, C., Mullen, D. J., Selamat, S. A., Campan, M., Offringa, I. A., & Marconett, C. N. (2022):**The sulfotransferase SULT1C2 is epigenetically activated and transcriptionally induced bytobacco exposure and is associated with patient outcome in lung adenocarcinoma.International Journal of Environmental Research and Public Health, 19(1).
73. **Kim, H. K., Zai, G., Muller, D. J., Husain, M. I., Lam, R. W., Frey, B. N., Soares, C. N.,Parikh, S. V., Milev, R., Foster, J. A., Turecki, G., Farzan, F., Mulsant, B. H.,Kennedy, S. H., Tripathy, S. J., & Kloiber, S. (2022):** Identification ofEndocannabinoid Predictors of Treatment Outcomes in Major DepressiveDisorder: A Secondary Analysis of the First Canadian Biomarker IntegrationNetwork in Depression (CAN-BIND 1) Study. Pharmacopsychiatry, 55(6), 297–303.
74. **King, E. S., Pierce, B., Hinczewski, M. & Scott, J. G. (2023):** Diverse mutant selection windows shape spatial heterogeneity in evolving populations. en. biorXiv.
75. **Labrie, M., Brugge, J. S., Mills, G. B. & Zervantonakis, I. K. (2022):** Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. en. Nature Reviews Cancer 22, 323–339. ISSN: 1474-1768 (June 2022).
76. **Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022):** The efficacy ofpsychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta-analytic evaluation of recent meta-analyses. WorldPsychiatry, 21(1), 133–145.
77. **Liu, S., Xiao, T., Huang, S., Li, X., Kong, W., Yang, Y., Zhang, Z., Ni, X., Lu, H., Zhang,M., Shang, D., & Wen, Y. (2022):** Population pharmacokinetics model forescitalopram in Chinese psychiatric patients: Effect of CYP2C19 and age.Frontiers in Pharmacology, 13.
78. **Magarbeh, L., Hassel, C., Choi, M., Islam, F., Marshe, V. S., Zai, C. C., Zuberi, R.,Gammal, R. S., Men, X., Scherf-Clavel, M., Enko, D., Frey, B. N., Milev, R.,Soares, C. N., Parikh, S. V., Placenza, F., Strother, S. C., Hassel, S., Taylor,V. H., ... Muller, D. J. (2023):** ABCB1 gene variants and AntidepressantTreatment Outcomes: A Systematic Review and Meta-analysis includingresults from the CAN-BIND-1 Study. Clinical Pharmacology and Therapeutics.
79. **Maltas, J. et al. (2023):** Drug dependence in cancer is exploitable by optimally constructed treatment holidays. en. Nature Ecology & Evolution 8, 147–162. ISSN: 2397-334X (Nov. 2023).
80. **Maltas, J. et al. (2023):** Frequency-dependent ecological interactions increase the prevalence, and shape the distribution, of pre-existing drug resistance. en. biorxiv (Mar. 2023).
81. **Min, J. L., Hemani, G., Hannon, E., Dekkers, K. F., Castillo-Fernandez, J., Luijk, R.,Carnero-Montoro, E., Lawson, D. J., Burrows, K., Suderman, M., Bretherick, A.D., Richardson, T. G., Klughammer, J., Iotchkova, V., Sharp, G., Al Khleifat, A.,Shatunov, A., Iacoangeli, A., McArdle, W. L., ... Relton, C. L. (2021):** Genomicand phenotypic insights from an atlas of genetic effects on DNA methylation.Nature Genetics, 53(9), 1311–1321.
82. **Nande, A. & Hill, A. L. (2022):** The risk of drug resistance during long-acting antimicrobial therapy. en. Proceedings of the Royal Society B: Biological Sciences 289, 20221444. ISSN: 0962-8452, 1471-2954 (Nov. 2022).
83. **Nunez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J.,Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., Wang, Z., & Singh, B.(2022):**Augmentation strategies for treatment resistant major depression: Asystematic review and network meta-analysis. Journal of Affective Disorders,302, 385–400.
84. **Poudel, A. N. et al. (2023):** The economic burden of antibiotic resistance: A systematic review and meta-analysis. en. PLOS ONE 18 (ed Karunasagar, I.) e0285170. ISSN: 1932-6203 (May 2023).

85. **Rajer, F. & Sandegren, L. (2022):** The Role of Antibiotic Resistance Genes in the Fitness Cost of Multiresistance Plasmids. en. mBio 13 (ed Cooper, V. S.) e03552–21. ISSN: 2150-7511 (Feb. 2022).

86. **Ramos, A., Sadeghi, S. & Tabatabaeian, H. (2021):** Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. en. International Journal of Molecular Sciences 22, 9451. ISSN: 1422-0067 (Aug. 2021).

87. **Ricardo-Silgado, M. L., Singh, S., Cifuentes, L., Decker, P. A., Gonzalez-Izundegui, D., Moyer, A. M., Hurtado, M. D., Camilleri, M., Bielinski, S. J., & Acosta, A.(2022):** Association between CYP metabolizer phenotypes and selectiveserotonin reuptake inhibitors induced weight gain: A retrospective cohort study.BMC Medicine, 20(1), 261.

88. **Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A. & Scott, J. G. (2023):** Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. en. npj Precision Oncology 7, 38. ISSN: 2397-768X (Apr. 2023).

89. **Stennett, H. L., Back, C. R. & Race, P. R. (2022):** Derivation of a Precise and Consistent Timeline for Antibiotic Development. en. Antibiotics 11, 1237. ISSN: 2079-6382 (Sept. 2022).

90. **Strobl, M. A. et al. (2022):** Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. Cancer Research 81, 1135–1147. ISSN: 0008-5472 (Feb. 2021).

91. **Vanacker, M., Lenuzza, N. & Rasigade, J.-P. (2023):** The ftness cost of horizontally transferred and mutational antimicrobial resistance in Escherichia coli. Frontiers in Microbiology 14, 1186920. ISSN: 1664-302X (June 2023).

92. **West, J. et al. (2023):** A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation. eLife 12 (ed White, R. M.) e84263. ISSN: 2050-084X (Mar. 2023).

93. **Zhang, J. et al. (2022):** A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer. en. Journal of Clinical Oncology 40, 5075–5075. ISSN: 0732-183X, 1527-7755 (June 2022).

94. **Zhang, J., Cunningham, J., Brown, J. & Gatenby, R. (2022):** Evolution-based mathematical models signifcantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. en. eLife 11, e76284. ISSN: 2050-084X (June 2022).